Drugs are designed to target. Pills dissolve at different speeds, different lubrication and fluids can be used to get drugs to a target area at its highest concentration. This is the best way to make sure the drugs are getting to the intended target at the best potency. Just think about the dosage that would need to be inject, swallowed etc.. to make the entire body feel the maximum potency, that could create many more safety issues than it is worth. It is best to target the known trouble area in most situations.
If you have noticed B-OM and B-UP did not have a phase I, that is Because B-ABBSI showed safety, so the phase I safety trial wasn't needed. Now if these drugs clear Phase III and they show impact to another issue there is definite potential for the FDA to take existing Data and allow a phase III but properly very rare. More like short Phase II trials like we are currently rolling out with B-UP and P. Don't forget B-OM has fast track and is a huge unmet medical need, B-OM could potentially be approved for use before or during Phase III trial. The same holds true for K if it hits a huge unmet need for a cancer(like retinoblastoma) It could be approved before or during a phase III and that would open the door to the other K indications.
It is a maze and I think IPIX has the blueprints to the maze, they are stacking the deck in their favor. Unfortunately for weak hands it is a hard hold, but I think most weak hands have folded. I believe we are on the cusp of seeing the plan unfold.